ANCHOR Study: Topical or ablative treatment in preventing anal cancer in patients with HIV and anal high-grade squamous intraepithelial lesions

The ANCHOR study has halted recruitment. The study is no longer enrolling new participants.

The ANCHOR Study has collected enough data to demonstrate that treatment of anal HSIL is effective in reducing the incidence of anal cancer in women and men living with HIV. All current participants are encouraged to contact their local study site for more details.

The study will close follow-up visits for current participants on March 31, 2024.

If there are additional questions or concerns, please contact us: 415-583-2277 or 415-353-9042 |

Phone: 844-448-2888 | Website: The Anchor Study